The Supreme Court has temporarily blocked a lower court's ruling that would have banned telehealth prescriptions for the abortion drug mifepristone. This action reinstates mail and telehealth access to the drug while the Court considers the case. The 5th Circuit Court of Appeals had previously ruled in favor of a ban.
Latest development
Media Coverage · May 4, 2026
The Supreme Court temporarily lifted a nationwide ban on doctors prescribing the abortion drug mifepristone during telehealth visits. This decision allows patients to access the drug through telehealth and mail while the court considers the case. The ban was previously reinstated by a lower court.
newspaper Read articleCourt
Court not identified
Awaiting court metadata
Docket
Not captured
Appellate
Stage
Active litigation
Active
Filed
Date unavailable
Not in the available feed
Latest Filing
Supreme Court temporarily lifts telehealth ban on abortion drug mifepristone
Media Coverage · May 04, 2026
Coverage
1 article
1 source tracked
Participants
1 Government Agency, 1 Related Organization
2 linked entities
Judge
Not assigned in feed
The court metadata has not been resolved yet, so Juryvine is keeping the page conservative until a reliable court match lands.
The newest docket activity we have is a media coverage dated May 04, 2026.
The visible party/entity graph currently includes Federal Bureau of Investigation, Oval Office.
Press monitoring has found 1 related article from 1 distinct source.
Supreme Court Temporarily Lifts Telehealth Ban on Abortion Drug Mifepristone is an active appellate matter.
Named participants include Federal Bureau of Investigation and Oval Office. The case is currently organized around Abortion drug regulation, Telehealth access, Supreme Court intervention, Mifepristone.
The Supreme Court has temporarily blocked a lower court's ruling that would have banned telehealth prescriptions for the abortion drug mifepristone. This action reinstates mail and telehealth access to the drug while the Court considers the case. The 5th Circuit Court of Appeals had previously ruled in favor of a ban.
On May 4, 2026, the docket recorded a media coverage: The Supreme Court temporarily lifted a nationwide ban on doctors prescribing the abortion drug mifepristone during telehealth visits. This decision allows patients to access the drug through telehealth and mail while the court considers the case. The ban was.
The next thing to watch is whether the latest media coverage produces a substantive order, a scheduling change, a settlement signal, or a filing that clarifies the parties' positions.
May 4 (UPI) -- The Supreme Court on Monday blocked a lower court's ruling that implemented a nationwide ban on doctors prescribing the abortion drug mifepristone during telehealth visits. The high court temporarily reinstated telehealth and mail access to the drug while it considers the case. Circuit Court of Appeals on Friday unanimously ruled in favor of the state of Louisiana in its case asking for the ban. One of the manufacturers of the drug, Danco, filed an appeal with the Supreme Court on
Open original open_in_newJuryvine summaries are generated from court records. Expand "Source" on any row to see the underlying filing.
The Supreme Court temporarily lifted a nationwide ban on doctors prescribing the abortion drug mifepristone during telehealth visits. This decision allows patients to access the drug through telehealth and mail while the court considers the case. The ban was previously reinstated by a lower court.
May 4 (UPI) -- The Supreme Court on Monday blocked a lower court's ruling that implemented a nationwide ban on doctors prescribing the abortion drug mifepristone during telehealth visits. The …
Sources tracked
1 outlet · 1 article
Timeline events
1 record on file
Last updated
2 hours, 7 minutes ago
Juryvine aggregates docket entries from PACER/CourtListener, press coverage, and GDELT signals. Ingestion timestamps do not appear in the What Changed feed — that reflects real court activity only.